Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

類似資料

• Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report
  著者:: Li, Jie, 等
  出版事項: (2020)
• EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib
  著者:: Gallant, Jean-Nicolas, 等
  出版事項: (2015)
• Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
  著者:: Xia, Pinghui, 等
  出版事項: (2018)
• A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
  著者:: Chen, Dong, 等
  出版事項: (2020)
• Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
  著者:: Wang, Jinguang, 等
  出版事項: (2018)